In premenopausal women with hypoactive sexual desire disorder or mixed disorder, responder rates at 1.75 mg bremelanotide were significantly higher than placebo for all 7 endpoints in the overall population.
In plain wordsIn premenopausal women with sexual dysfunction, more women responded to bremelanotide 1.75 mg than to placebo on all 7 measures.
- Peptide
- Bremelanotide (PT-141)
- Outcome
- IncreaseResponder rates across 7 patient-reported endpoints
- Study
n: not reported in source
- Comparator
- Placebo
- Outcome group
- Sexual function · Reproductive and sexual health
- Studied dose
- 1.75 mgAs given in this study (human).
Source sentences
For all 7 endpoints, responder rates at the 1.75 mg dose in the overall modified intention-to-treat population achieved statistical significance compared with placebo (P ≤ .03).
1 context sentence(design, population, supporting numbers)
To identify the minimal clinically important difference (MCID) for selected scores on questionnaires assessing female sexual functioning and to use these differences to analyze the response in a large, controlled, phase 2b, dose-finding study of bremelanotide in premenopausal women with hypoactive s…